Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (141-150 of 222) with videos related to

Pageof 23
Sort By:
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
AIDS (London, England)|April 25, 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/IPaul E Sax, Kristen Andreatta, Jean-Michel Molina, et al.
The New England Journal of Medicine|August 9, 2002
Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little, Sarah Holte, Jean-Pierre Routy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2019
Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record DataAnk E Nijhawan, Lisa R Metsch, Song Zhang, et al.
Scientific Reports|August 25, 2015
Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral TherapyMarta Massanella, Sara Gianella, Rachel Schrier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 31, 2020
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy InitiationTrevor A Crowell, Justin Ritz, Robert W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2007
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patientsBrookie M Best, Miguel Goicoechea, Mallory D Witt, et al.
Journal of Virology|February 14, 2004
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown, Simon D W Frost, Benjamin Good, et al.
Pageof 23

Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
AIDS (London, England)|April 25, 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/IPaul E Sax, Kristen Andreatta, Jean-Michel Molina, et al.
The New England Journal of Medicine|August 9, 2002
Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little, Sarah Holte, Jean-Pierre Routy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2019
Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record DataAnk E Nijhawan, Lisa R Metsch, Song Zhang, et al.
Scientific Reports|August 25, 2015
Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral TherapyMarta Massanella, Sara Gianella, Rachel Schrier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 31, 2020
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy InitiationTrevor A Crowell, Justin Ritz, Robert W Coombs, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2007
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patientsBrookie M Best, Miguel Goicoechea, Mallory D Witt, et al.
Journal of Virology|February 14, 2004
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown, Simon D W Frost, Benjamin Good, et al.
Pageof 23